Chlamydia psittaci infection and clinicopathologic analysis of ocular adnexal lymphomas in Korea. 2007

Changhoon Yoo, and Min-Hee Ryu, and Jooryung Huh, and Ji Hyun Park, and Hye Jin Kang, and Hyo Sook Ahn, and Yongjae Lee, and Myoung Joon Kim, and Hyoungnam Lee, and Tae Won Kim, and Heung Moon Chang, and Jae-Lyun Lee, and Yoon-Koo Kang
Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

Ocular adnexal lymphoma (OAL) is a mostly extranodal marginal zone lymphoma (EMZL). Recent findings have suggested an association between Chlamydia psittaci (Cp) infection and OAL. We sought to confirm this issue and to analyze the clinicopathologic characteristics of OAL in Korea. Between 1993 and 2004, 33 OAL cases were identified at the Asan Medical Center, Seoul, Korea. DNA was extracted from paraffin-embedded tissues, and touchdown enzyme time release polymerase chain reaction was performed to identify three Chlamydia species (Cp, C. tracomatis, and C. pneumoniae). The same procedures were also performed in 21 samples from patients with non-neoplastic ocular adnexal disease (NNOAD). All OAL cases were EMZL. Cp DNA was detected in 26/33 (79%) OAL samples compared with 5/21 (23%) NNOAD samples (P < 0.001). With a median follow-up of 38.5 months (range: 1-105 months), the 5-year progression-free survival (PFS) and overall survival (OS) rates of OAL patients were 72% and 93%, respectively. Clinicopathologic characteristics, recurrence rate, PFS, and OS were not associated with Cp infection. Our study demonstrates an association between OAL and Cp infection in Korea, suggesting that Cp plays a role as a causative antigen in Korean OAL patients.

UI MeSH Term Description Entries
D007723 Korea Former kingdom, located on Korea Peninsula between Sea of Japan and Yellow Sea on east coast of Asia. In 1948, the kingdom ceased and two independent countries were formed, divided by the 38th parallel.
D009956 Psittacosis Infection with CHLAMYDOPHILA PSITTACI (formerly Chlamydia psittaci), transmitted to humans by inhalation of dust-borne contaminated nasal secretions or excreta of infected BIRDS. This infection results in a febrile illness characterized by PNEUMONITIS and systemic manifestations. Ornithosis,Ornithoses,Psittacoses
D011241 Prednisone A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver. Dehydrocortisone,delta-Cortisone,Apo-Prednisone,Cortan,Cortancyl,Cutason,Dacortin,Decortin,Decortisyl,Deltasone,Encorton,Encortone,Enkortolon,Kortancyl,Liquid Pred,Meticorten,Orasone,Panafcort,Panasol,Predni Tablinen,Prednidib,Predniment,Prednison Acsis,Prednison Galen,Prednison Hexal,Pronisone,Rectodelt,Sone,Sterapred,Ultracorten,Winpred,Acsis, Prednison
D002691 Chlamydophila psittaci A genus of CHLAMYDOPHILA infecting primarily birds. It contains eight known serovars, some of which infect more than one type of host, including humans. Chlamydia psittaci
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D003561 Cytarabine A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472) Ara-C,Arabinofuranosylcytosine,Arabinosylcytosine,Cytosine Arabinoside,Aracytidine,Aracytine,Cytarabine Hydrochloride,Cytonal,Cytosar,Cytosar-U,beta-Ara C,Ara C,Arabinoside, Cytosine,Cytosar U,beta Ara C
D003907 Dexamethasone An anti-inflammatory 9-fluoro-glucocorticoid. Hexadecadrol,Decaject,Decaject-L.A.,Decameth,Decaspray,Dexasone,Dexpak,Hexadrol,Maxidex,Methylfluorprednisolone,Millicorten,Oradexon,Decaject L.A.
D004269 DNA, Bacterial Deoxyribonucleic acid that makes up the genetic material of bacteria. Bacterial DNA

Related Publications

Changhoon Yoo, and Min-Hee Ryu, and Jooryung Huh, and Ji Hyun Park, and Hye Jin Kang, and Hyo Sook Ahn, and Yongjae Lee, and Myoung Joon Kim, and Hyoungnam Lee, and Tae Won Kim, and Heung Moon Chang, and Jae-Lyun Lee, and Yoon-Koo Kang
April 2004, Journal of the National Cancer Institute,
Changhoon Yoo, and Min-Hee Ryu, and Jooryung Huh, and Ji Hyun Park, and Hye Jin Kang, and Hyo Sook Ahn, and Yongjae Lee, and Myoung Joon Kim, and Hyoungnam Lee, and Tae Won Kim, and Heung Moon Chang, and Jae-Lyun Lee, and Yoon-Koo Kang
January 2007, Leukemia & lymphoma,
Changhoon Yoo, and Min-Hee Ryu, and Jooryung Huh, and Ji Hyun Park, and Hye Jin Kang, and Hyo Sook Ahn, and Yongjae Lee, and Myoung Joon Kim, and Hyoungnam Lee, and Tae Won Kim, and Heung Moon Chang, and Jae-Lyun Lee, and Yoon-Koo Kang
March 2006, Journal of the National Cancer Institute,
Changhoon Yoo, and Min-Hee Ryu, and Jooryung Huh, and Ji Hyun Park, and Hye Jin Kang, and Hyo Sook Ahn, and Yongjae Lee, and Myoung Joon Kim, and Hyoungnam Lee, and Tae Won Kim, and Heung Moon Chang, and Jae-Lyun Lee, and Yoon-Koo Kang
December 2006, Leukemia research,
Changhoon Yoo, and Min-Hee Ryu, and Jooryung Huh, and Ji Hyun Park, and Hye Jin Kang, and Hyo Sook Ahn, and Yongjae Lee, and Myoung Joon Kim, and Hyoungnam Lee, and Tae Won Kim, and Heung Moon Chang, and Jae-Lyun Lee, and Yoon-Koo Kang
September 2008, Clinical cancer research : an official journal of the American Association for Cancer Research,
Changhoon Yoo, and Min-Hee Ryu, and Jooryung Huh, and Ji Hyun Park, and Hye Jin Kang, and Hyo Sook Ahn, and Yongjae Lee, and Myoung Joon Kim, and Hyoungnam Lee, and Tae Won Kim, and Heung Moon Chang, and Jae-Lyun Lee, and Yoon-Koo Kang
August 2016, Experimental and molecular pathology,
Changhoon Yoo, and Min-Hee Ryu, and Jooryung Huh, and Ji Hyun Park, and Hye Jin Kang, and Hyo Sook Ahn, and Yongjae Lee, and Myoung Joon Kim, and Hyoungnam Lee, and Tae Won Kim, and Heung Moon Chang, and Jae-Lyun Lee, and Yoon-Koo Kang
March 2007, Leukemia & lymphoma,
Changhoon Yoo, and Min-Hee Ryu, and Jooryung Huh, and Ji Hyun Park, and Hye Jin Kang, and Hyo Sook Ahn, and Yongjae Lee, and Myoung Joon Kim, and Hyoungnam Lee, and Tae Won Kim, and Heung Moon Chang, and Jae-Lyun Lee, and Yoon-Koo Kang
March 2006, British journal of haematology,
Changhoon Yoo, and Min-Hee Ryu, and Jooryung Huh, and Ji Hyun Park, and Hye Jin Kang, and Hyo Sook Ahn, and Yongjae Lee, and Myoung Joon Kim, and Hyoungnam Lee, and Tae Won Kim, and Heung Moon Chang, and Jae-Lyun Lee, and Yoon-Koo Kang
August 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Changhoon Yoo, and Min-Hee Ryu, and Jooryung Huh, and Ji Hyun Park, and Hye Jin Kang, and Hyo Sook Ahn, and Yongjae Lee, and Myoung Joon Kim, and Hyoungnam Lee, and Tae Won Kim, and Heung Moon Chang, and Jae-Lyun Lee, and Yoon-Koo Kang
August 2008, Leukemia research,
Copied contents to your clipboard!